Company intelligence / Profile preview

Primex Pharmaceuticals

Ownership: Private
Development stage: Commercial

Overview

Primex Pharmaceuticals has received marketing authorization approvals across multiple EU countries for OZALIN® (ADV6209), an oral midazolam solution for moderate sedation in children from 6 months to 17 years before therapeutic or diagnostic procedures, and as premedication prior to anaesthesia[7].

Therapeutic areas: OtherNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

Recofol N

Unknown

Partnerships

Global partner network operating in over 40 countries

Beyond the preview

Go deeper on Primex Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primex Pharmaceuticals.

Explore the full profile